SuperworthQuidelOrtho price to free cash flow QDEL
Market value divided by free cash flow over the last twelve months, since 2023.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 141×
- Oct 2025
- 3-year median
- 37.5×
- 3-year range
- 14.2× to 159×
- Peer median
- 23.2×
QuidelOrtho's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.
It was last meaningful in Oct 2025, at 141×.
On the days it had one over the last 3 years, its median was 37.5×, from 14.2× in Jun 2023 to 159× in Oct 2025.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2025 | 141× | 125× | 159× |
| 2024 | 40.1× | 19.0× | 45.6× |
| 2023 | 33.5× | 14.2× | 51.5× |
Against its peers
Companies in Medical - Diagnostics & Research nearest QuidelOrtho's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| QDELQuidelOrtho | n/m |
| NRCNRC Health | 22.4× |
| CDNACareDx | n/m |
| VCYTVeracyte | 23.2× |
| BLLNBillionToOne | 153× |
| LNTHLantheus | 16.8× |
| CAICaris Life Sciences | 73.0× |
| Peer median | 23.2× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on QuidelOrtho
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.